ESTIMATION OF THE WARFARIN DOSE IN HEART FAILURE PATIENTS WITH IMPLANTED MECHANICAL CIRCULATORY SUPPORT DEVICE
Relevance. Left ventricular assist device (LVAD) is an alternative treatment for heart failure (HF) patients which improves patient’s quality of life at their end-stage. Despite to the improvement LVAD is beleaguered with thrombosis/bleeding complications in 70% of HF patients after implantation. An anticoagulant treatment of warfarin is usually prescribed to reduce thrombosis complications. However, due to the incorrect dosage of the treatment thrombosis/ bleeding complications still happen. Warfarin dose could be identified by genetic variants of vitamin K-epoxide reductase complex (VKORC1) and the cytochrome P450-2C9 (CYP2C9) which account for 50% of dose variability.
Aim. The aim of our investigation is to identify variability of warfarin dose according to the genotype polymorphisms of genes and their difference from the clinical dosage in HF patients.
Materials and methods. The case series study included 98 HF patients (without complications – 74 patients, with complications – 24 patients) with prescribed warfarin treatment after device implantation. Clinical warfarin dosage difference was identified between genotype polymorphisms of rs9923231, rs9934438 in VKORC1 gene. Furthermore, warfarin dosage was calculated according to the genetic test results and compared with clinical dosage.
Results. Warfarin dosage according to the clinical protocol between three genotypes of polymorphisms in VKORC1 gene showed significant difference. HF patients were prescribed with higher warfarin dosage with wild type genotype polymorphism of rs9934438 in VKORC1 gene than with mutant genotype < 2.5mg (3.88 ± 1.25 vs. 2.44 ± 0.81, p = 0.00005).
Conclusion. Genotype-guided warfarin dosing may estimate accurate dose and potentially improve outcomes in LVAD patients.
Number of Views: 136
Category of articles:
Original articles
Bibliography link
Zhalbinova M.R., Rakhimova S.E., Andosova S.A., Akilzhanova G.A., Bekbosynova M.S., Akilzhanova A.R. Estimation of the warfarin dose in heart failure patients with implanted mechanical circulatory support device // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 59-66. doi 10.34689/SH.2023.25.1.007 Жалбинова М.Р., Рахимова С.Е., Андосова С.А., Акильжанова Г.А., Бекбосынова М.С., Акильжанова А.Р. Расчет дозы варфарина у пациентов с сердечной недостаточностью с имплантированным устройством механической поддержки кровообращения // Наука и Здравоохранение. 2023. 1(Т.25). С. 59-66. doi 10.34689/SH.2023.25.1.007Related publications:
A COMPARATIVE ANALYSIS OF 24-HOUR DIETARY RECALLS AND FOOD FREQUENCY QUESTIONNAIRES ADMINISTERED SIMULTANEOUSLY IN THE KAZAKHSTANI POPULATION
ANALYSIS OF PATIENT SATISFACTION WITH THE QUALITY OF ORGANIZATION OF TREATMENT IN FOREIGN CLINICS
CLINICAL AND LABORATORY PREDICTORS OF THE SEVERITY OF COVID-19 INFECTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
POST-MARKETING STUDY OF THE CLINICAL EFFICACY AND SAFETY OF GRIPMAX NOS IN THE TREATMENT OF ACUTE RESPIRATORY INFECTIONS OF THE UPPER RESPIRATORY TRACT
EXPERIENCE IN IMPROVING SURGICAL TREATMENT WHEN IMPOSING A STOMA IN CHILDREN WITH HIRSPRUNG'S DISEASE